Technology • NASDAQ
According to Zyberno, GoodRx Holdings, Inc. (GDRX) is not a buy — WEAK BUSINESS (43/100) with a negative Margin of Safety of +6.1% and a Brina Gap of -18.9% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, GoodRx Holdings, Inc. (GDRX) trades at $3.53 against an estimated intrinsic value per share of $3.76 — a +6.1% Margin of Safety based on Owner Earnings of $165.81M TTM, projected at -9.2% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -18.9% weakens the case: based on the company's ROIC (4.9%) and reinvestment rate (-92.5%), the business can fundamentally grow at -4.6% — but the current enterprise value implies the market expects 14.4%. This places GDRX in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of -8.0% annually.
Over the trailing twelve months, GDRX generated $165.81M in Owner Earnings. Capital was deployed as follows: $12.57M returned via share buybacks, $4.52M invested in capital expenditures. Reinvestment rate: -92.5%. Owner Earnings have declined at 9.2% annually over the trailing five years using log-linear regression.